Event-Driven Stocks

PORTOLA PHARMACEUTICALS INC

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs1 good5 warning1 severedetails ↓

Financials

SEC XBRL · annual
 FY19FY18FY17FY16FY15FY14
Revenue$116.6M$40.1M$22.5M$35.5M
Operating income−$271.3M−$345.3M−$272.7M−$269.6M−$227.2M−$137.6M
Net income−$78.2M−$84.2M−$286.1M−$269.0M−$226.5M−$137.1M
Total assets$578.5M$386.4M$571.7M$343.4M$502.9M$416.5M
Total liabilities$448.7M$295.9M$222.2M$150.7M$72.6M$68.7M
Equity$129.8M$88.4M$346.9M$190.5M$427.4M$347.8M
EPS (diluted)$-3.19
Shares out.66.8M65.4M56.6M56.4M49.0M41.0M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2019
Operating margin
−232.6%
Net margin
−67.0%
Return on equity
−60.2%
Return on assets
−13.5%
Return on capital (ROCE)
−57.0%
Liabilities / assets
77.6%
Debt / equity
3.46×
Book value / share
$1.94
Revenue growth (YoY)
190.7%
Net income growth (YoY)

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2019
Altman Z″ (distress)
-9.00distress
Accruals / assets
27.6%high accruals
Piotroski F-Score
3/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
37
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 0Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

1 severe5 warning1 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Revenue is growing year-over-year

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Insider transactions

SEC Form 4 · most recent
0 acquisitions1 disposalsnet 20,475 shares · last 1
InsiderDateTypeSharesPrice
Bird Jeffrey WDirectorJul 2, 2020D20,475$18.00

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.